ENWAR
Senolytics and the Clearance of Zombie Cells: A Phase II Clinical Analysis
October 20, 2024Dr. James Morrison, Dr. Sarah Kim, Dr. Raj GuptaBiotechnology
senolyticssenescent cellsagingclinical trial
ABSTRACT
Our Phase II clinical trial examined the efficacy of a novel senolytic compound in clearing senescent cells from human subjects aged 60-80. Results indicate a 35% reduction in senescent cell markers a...
FULL PAPER ACCESS REQUIRED
Subscribe to the ODiN Archive for unlimited access to all papers, or purchase this paper individually for $19.
Citation
Durahuman Research. (2024). Senolytics and the Clearance of Zombie Cells. LASO Program.